![Jackie Papkoff](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jackie Papkoff
Keine laufenden Positionen mehr
Karriereverlauf von Jackie Papkoff
Ehemalige bekannte Positionen von Jackie Papkoff
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
California Innovation Center | Corporate Officer/Principal | - | - |
ASSEMBLY BIOSCIENCES, INC. | Corporate Officer/Principal | 02.04.2018 | - |
EVELO BIOSCIENCES, INC. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
CFD Therapeutics, Inc.
![]() CFD Therapeutics, Inc. Medical SpecialtiesHealth Technology CFD Therapeutics, Inc. (CFD), is being created to develop novel cancer therapeutics stemming from discoveries made previously by diaDexus. CFD will specifically focus on the development of therapeutic monoclonal antibodies directed against proprietary ovarian, pancreatic, breast, colon, prostate and lung cancer targets licensed from diaDexus. diaDexus, Inc. and San Francisco-based Biotechnology Value Fund L.P | Technik-/Wissenschafts-/F&E-Leiter | 17.09.2009 | - |
Ausbildung von Jackie Papkoff
The Salk Institute for Biological Studies | Doctorate Degree |
University of California San Diego | Doctorate Degree |
University of California, Santa Cruz | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 8 |
Operativ
Chief Tech/Sci/R&D Officer | 2 |
Corporate Officer/Principal | 2 |
Doctorate Degree | 2 |
Sektoral
Consumer Services | 4 |
Health Technology | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
ASSEMBLY BIOSCIENCES, INC. | Health Technology |
EVELO BIOSCIENCES, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
CFD Therapeutics, Inc.
![]() CFD Therapeutics, Inc. Medical SpecialtiesHealth Technology CFD Therapeutics, Inc. (CFD), is being created to develop novel cancer therapeutics stemming from discoveries made previously by diaDexus. CFD will specifically focus on the development of therapeutic monoclonal antibodies directed against proprietary ovarian, pancreatic, breast, colon, prostate and lung cancer targets licensed from diaDexus. diaDexus, Inc. and San Francisco-based Biotechnology Value Fund L.P | Health Technology |
California Innovation Center |
- Börse
- Insiders
- Jackie Papkoff
- Erfahrung